Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-12-2009 | Epidemiology

Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling

Authors: Julie Lemieux, Carl Amireault, Louise Provencher, Elizabeth Maunsell

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Scalp cooling is an intervention used to decrease the degree of chemotherapy-induced alopecia. The objective is to determine the incidence of scalp metastases among women with early breast cancer who received neoadjuvant or adjuvant chemotherapy. We conducted a retrospective cohort study of women with breast carcinoma diagnosed between June 1, 1998 and June 30, 2002. The median follow-up was 5.8 years (±1.7) for the scalp cooling group (n = 553) and 5.4 years (±1.7) for the non-scalp cooling group (n = 87). The incidence of scalp metastases was 1.1% (6 cases out of 553 patients) among women who used scalp cooling in the neoadjuvant or adjuvant setting and 1.2% also (1 case out of 87 patients) among women who did not use scalp cooling in the neoadjuvant or adjuvant setting. The incidence of scalp metastases was low and no case presented as an isolated site of relapse.
Footnotes
1
Cyclophosphamide, methotrexate, 5-fluorouracil.
 
2
Doxorubicin-cyclophosphamide. CMF cyclophosphamide-methotrexate-5-fluouracil.
 
Literature
1.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0 CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.​1016/​S0140-6736(05)66544-0 CrossRef
3.
go back to reference Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17:317–328. doi:10.1002/pon.1245 CrossRefPubMed Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17:317–328. doi:10.​1002/​pon.​1245 CrossRefPubMed
4.
go back to reference Sedlacek SM (2006) Persistent significant alopecia (PSA) from adjuvant docetaxel after doxorubicin/cyclophosphamide (AC) chemotherapy in women with breast cancer. Breast Cancer Res Treat. Abstract no 2105 Sedlacek SM (2006) Persistent significant alopecia (PSA) from adjuvant docetaxel after doxorubicin/cyclophosphamide (AC) chemotherapy in women with breast cancer. Breast Cancer Res Treat. Abstract no 2105
9.
go back to reference Camp-Sorrell D (1991) Scalp hypothermia devices: current status. ONS News 6:1–5 Camp-Sorrell D (1991) Scalp hypothermia devices: current status. ONS News 6:1–5
11.
go back to reference Gates O (1937) Cutaneous metastases of malignant disease. Am J Cancer 30:718–730 Gates O (1937) Cutaneous metastases of malignant disease. Am J Cancer 30:718–730
14.
go back to reference Fay T (1938) Correlation of body segmental temperature and its relation to the location of carcinomatous metastasis. Surg Gynecol Obstet 66:512–514 Fay T (1938) Correlation of body segmental temperature and its relation to the location of carcinomatous metastasis. Surg Gynecol Obstet 66:512–514
16.
go back to reference Witman G, Cadman E, Chen M (1981) Misuse of scalp hypothermia. Cancer Treat Rep 65:507–508PubMed Witman G, Cadman E, Chen M (1981) Misuse of scalp hypothermia. Cancer Treat Rep 65:507–508PubMed
20.
go back to reference Middleton J, Franks D, Buchanan RB et al (1985) Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep 69:373–375PubMed Middleton J, Franks D, Buchanan RB et al (1985) Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep 69:373–375PubMed
22.
go back to reference Spaeth D, Luporsi E, Coudert B et al (2008) Efficacy and safety of cooling helmets for the prevention of chemotherapy-induced alopecia: a prospective study of 911 patients (pts). PASCO 26:517s Spaeth D, Luporsi E, Coudert B et al (2008) Efficacy and safety of cooling helmets for the prevention of chemotherapy-induced alopecia: a prospective study of 911 patients (pts). PASCO 26:517s
23.
go back to reference van den Hurk C, Coebergh JWW, van de Poll-Franse LV et al (2008) Some aspects of scalp cooling in breast cancer patients receiving chemotherapy. EJC suppl 6:201 van den Hurk C, Coebergh JWW, van de Poll-Franse LV et al (2008) Some aspects of scalp cooling in breast cancer patients receiving chemotherapy. EJC suppl 6:201
Metadata
Title
Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling
Authors
Julie Lemieux
Carl Amireault
Louise Provencher
Elizabeth Maunsell
Publication date
01-12-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0342-0

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine